Ostermann Marlies, Legrand Matthieu, Meersch Melanie, Srisawat Nattachai, Zarbock Alexander, Kellum John A
Department of Critical Care, Guy's & St Thomas' NHS Foundation Hospital, London, SE1 7EH, UK.
Department of Anesthesia and Perioperative Care, Division of Critical Care Medicine, University of California San Francisco, San Francisco, USA.
Ann Intensive Care. 2024 Sep 15;14(1):145. doi: 10.1186/s13613-024-01360-9.
Acute kidney injury (AKI) is a multifactorial syndrome with a high risk of short- and long-term complications as well as increased health care costs. The traditional biomarkers of AKI, serum creatinine and urine output, have important limitations. The discovery of new functional and damage/stress biomarkers has enabled a more precise delineation of the aetiology, pathophysiology, site, mechanisms, and severity of injury. This has allowed earlier diagnosis, better prognostication, and the identification of AKI sub-phenotypes. In this review, we summarize the roles and challenges of these new biomarkers in clinical practice and research.
急性肾损伤(AKI)是一种多因素综合征,具有短期和长期并发症的高风险,同时医疗成本也会增加。AKI的传统生物标志物血清肌酐和尿量存在重要局限性。新的功能及损伤/应激生物标志物的发现,使得对病因、病理生理学、损伤部位、机制及严重程度能够进行更精确的描述。这有助于早期诊断、更好地预测预后以及识别AKI的亚表型。在本综述中,我们总结了这些新生物标志物在临床实践和研究中的作用及挑战。